
June 12 (Reuters) - UCB SA UCB.BR:
DAPIROLIZUMAB PEGOL PHASE 3 DATA IN SLE PRESENTED AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR) SHOW IMPROVEMENT IN FATIGUE AND REDUCTION IN DISEASE ACTIVITY
DZP SHOWED CONSISTENT IMPROVEMENTS IN FATIGUE, A COMMON AND DEBILITATING SYMPTOM OF SYSTEMIC LUPUS ERYTHEMATOSUS
DAPIROLIZUMAB PEGOL (DZP) SHOWED EFFICACY ACROSS MULTIPLE CLINICAL ENDPOINTS IN PHOENYCS GO STUDY